Fulgent Genetics SEC Filings

Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, Inc. (FLGT), reported the sale of 1,063 shares of the issuer's common stock on 09/03/2025. The filing states the shares were sold to satisfy tax withholding obligations arising from the vesting of restricted stock units originally granted on 02/28/2022. The shares were sold in multiple transactions at prices ranging from $21.92 to $22.175, with a reported weighted-average sale price of $22.0267. Following the reported sale, the reporting person beneficially owns 957,085 shares, held directly.

Xie Jian, President and COO of Fulgent Genetics, Inc. (FLGT), reported the sale of 1,128 shares of the issuer's common stock on 09/03/2025 at a weighted-average sale price of $22.0267 per share to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on 02/28/2022. After the reported sale, Mr. Xie beneficially owned 364,121 shares directly and held an additional 220,816 shares indirectly through The Hsieh Family Dynasty Trust, dated January 27, 2010. The Form 4 was executed by Paul Kim as attorney-in-fact.

Paul Kim, identified as CFO and Treasurer of Fulgent Genetics, Inc. (FLGT), reported a transaction dated 09/01/2025 in which 1,131 shares of the issuer's common stock were disposed of under transaction code F at a price of $22.17 per share. The filing explains these shares were withheld to satisfy tax withholding obligations arising from the vesting of restricted stock units originally granted on February 28, 2022. After the withholding, the reporting person beneficially owns 336,861 shares, held directly. The Form 4 is signed by Paul Kim on 09/03/2025.

Fulgent Genetics, Inc. (FLGT) filed a Form 144 notice reporting a proposed sale of 1,128 shares of common stock through Morgan Stanley Smith Barney on 09/03/2025, with an aggregate market value of $24,846.15. The filer acquired the shares as restricted stock vesting on 02/28/2022 as equity compensation (32,000 shares acquired on that date). The filing shows prior sales by the same person in August 2025 totaling 1,895 shares for gross proceeds of $40,725.28. Total shares outstanding are reported as 30,609,044.

Form 144 filed for Fulgent Genetics, Inc. (FLGT) reports a proposed sale of 1,063 shares of common stock through Morgan Stanley Smith Barney with an aggregate market value of $23,414.42, listed for sale on NASDAQ and an approximate sale date of 09/03/2025. The shares were acquired by the seller as restricted stock that vested on 02/28/2022 and were granted as equity compensation for services rendered. The filer also reports two recent sales in August 2025 totaling 1,491 shares for gross proceeds of $32,042.96. The filing includes the seller's representation that they are unaware of any undisclosed material adverse information about the issuer.

Fulgent Genetics (FLGT) insider sale by President & COO: On 08/27/2025, reporting person Xie Jian sold 1,199 shares of Fulgent common stock at a weighted-average price of $21.4847 to satisfy tax withholding from restricted stock units that vested from a Feb 26, 2024 RSU grant. After the sale, Mr. Xie beneficially owns 365,249 shares directly and 220,816 shares indirectly through The Hsieh Family Dynasty Trust (where he serves on the investment committee and disclaims beneficial interest except for any pecuniary interest). The Form 4 reports the sale as a routine, nondiscretionary transaction to cover tax obligations rather than an open-market cash-raising sale.

Ming Hsieh, Chief Executive Officer, Director and 10% owner of Fulgent Genetics (FLGT), reported a small disposition of company stock on 08/26/2025. The Form 4 shows 2,944 shares were withheld to satisfy tax withholding obligations arising from the vesting of restricted stock units, at an effective price of $21.47 per share. After the transaction Mr. Hsieh directly beneficially owns 804,281 shares. He also reports indirect holdings of 7,895,115 shares held by a Dynasty Trust, 220,816 shares held by the Ming Hsieh Trust, and two 1,000-share Uniform Transfers to Minor Act accounts for which he is custodian. The form was signed by an attorney-in-fact on 08/28/2025.

Kim Paul, Chief Financial Officer and Treasurer of Fulgent Genetics, Inc. (FLGT), reported a change in beneficial ownership. On 08/26/2025 the reporting person had 1,166 shares of common stock disposed of at a price of $21.47 per share, leaving 337,992 shares beneficially owned after the transaction. The filing explains those shares were withheld to satisfy tax-withholding obligations tied to restricted stock units that vested from a grant dated 02/26/2024 (originally reported 02/28/2024). The Form 4 is signed by Paul Kim on 08/28/2025.

Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, Inc. (FLGT), reported a sale of 943 shares of the issuer's common stock on 08/27/2025 to satisfy tax withholding related to restricted stock units that vested from a grant made on 02/26/2024. The shares were sold in multiple transactions at prices ranging from $21.28 to $21.66, with a reported weighted-average sale price of $21.4847. After the reported sale, the reporting person beneficially owned 958,148 shares directly. The Form 4 was signed by an attorney-in-fact, Paul Kim, on 08/28/2025. No derivative transactions or other amendments are disclosed in this filing.